Nissay Asset Management Corp Japan ADV bought a new stake in shares of Mylan NV (NASDAQ:MYL) during the 1st quarter, HoldingsChannel.com reports. The firm bought 106,393 shares of the company’s stock, valued at approximately $3,015,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Pzena Investment Management LLC raised its holdings in Mylan by 0.3% in the 1st quarter. Pzena Investment Management LLC now owns 21,027,676 shares of the company’s stock worth $595,924,000 after purchasing an additional 71,010 shares during the period. Stephens Inc. AR raised its holdings in Mylan by 10.1% in the 1st quarter. Stephens Inc. AR now owns 13,378 shares of the company’s stock worth $379,000 after purchasing an additional 1,231 shares during the period. South Dakota Investment Council raised its holdings in Mylan by 6.3% in the 1st quarter. South Dakota Investment Council now owns 43,700 shares of the company’s stock worth $1,238,000 after purchasing an additional 2,600 shares during the period. Victory Capital Management Inc. raised its holdings in Mylan by 5.1% in the 1st quarter. Victory Capital Management Inc. now owns 87,655 shares of the company’s stock worth $2,484,000 after purchasing an additional 4,288 shares during the period. Finally, Signition LP raised its holdings in Mylan by 22.2% in the 1st quarter. Signition LP now owns 46,803 shares of the company’s stock worth $1,326,000 after purchasing an additional 8,512 shares during the period. Institutional investors and hedge funds own 83.69% of the company’s stock.
A number of equities analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $41.00 target price on shares of Mylan in a report on Monday, April 1st. BidaskClub raised Mylan from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 30th. Royal Bank of Canada decreased their price target on Mylan to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. Mizuho reissued a “hold” rating on shares of Mylan in a report on Tuesday. Finally, BTIG Research decreased their price target on Mylan to $35.00 and set a “buy” rating on the stock in a report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $37.35.
Shares of Mylan stock opened at $20.41 on Thursday. The stock has a market cap of $10.35 billion, a PE ratio of 4.46, a PEG ratio of 1.04 and a beta of 1.44. The company has a quick ratio of 0.85, a current ratio of 1.51 and a debt-to-equity ratio of 1.20. Mylan NV has a twelve month low of $19.40 and a twelve month high of $42.50.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.03. The firm had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.96 earnings per share. Analysts anticipate that Mylan NV will post 4.28 earnings per share for the current fiscal year.
In other news, insider Paul Campbell sold 11,533 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.81% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).